With novel compounds selectively targeting TP53, therapeutic approaches targeting the TP53 pathway are progressing in early clinical testing and could soon be considered the standard of care for individuals with AML who are 60 and older and ineligible for intense therapy or who have been diagnosed with advanced disease. Here, TP53 is linked to acute myeloid leukemia.